Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

CONTINUING CONNECTED TRANSACTIONS AND CONNECTED TRANSACTION IN RELATION TO (1) TECHNOLOGY TRANSFER AND COMMERCIAL PRODUCTION; AND (2) EQUIPMENT BUYBACK

INTRODUCTION

The Board announces that on 17 November 2026 (after trading hours), Eddingpharm Zhuhai, an indirect wholly-owned subsidiary of the Company, entered into the Agreement with Taizhou EOC, pursuant to which Eddingpharm Zhuhai commissions Taizhou EOC to conduct process technology transfer, regulatory filing support and commercial production of two Products: (i) Rujianing; and (ii) Mulpleta, at Taizhou EOC's facility.

Under the Agreement, Eddingpharm Zhuhai will also provide the equipment required for commercial production of the Products, which will be purchased by Taizhou EOC through deductions from the Product purchase payments at a rate of a lower double-digit percentage of the tax-inclusive total commercial product purchase price per unit payable by Eddingpharm Zhuhai until the total purchase price of such equipment has been fully offset.

IMPLICATIONS UNDER THE LISTING RULES

Taizhou EOC is a connected person of the Company under the Listing Rules. Accordingly, the transactions contemplated under the Agreement (other than the Equipment Buyback) constitute continuing connected transactions (the "Continuing Connected Transactions"), and the Equipment Buyback constitutes a one-off connected transaction, of the Company under Chapter 14A of the Listing Rules.

Pursuant to Rule 14A.81 of the Listing Rules, the Continuing Connected Transactions and the Equipment Buyback are aggregated as they were entered into with the same connected person under the same agreement. As the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the proposed annual caps for the Continuing Connected Transactions and the maximum consideration for the Equipment Buyback, on an aggregated basis, exceed 0.1% but all are less than 5%, the transactions contemplated under the Agreement are subject to the reporting, announcement and, in the case of the Continuing Connected Transactions, annual review requirements, but exempt from the circular and independent shareholders' approval requirements, under Chapter 14A of the Listing Rules.

BACKGROUND

Eddingpharm Zhuhai is responsible for the Group's pharmaceutical development and commercialization activities in the PRC. The Group is seeking to establish a stable and controllable domestic technology transfer, registration and commercial production and supply arrangement for the Products. Rujianing is a novel, potent, selective and orally bioavailable CDK4/6 inhibitor launched in China for use in combination with endocrine therapy for the treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer. It was included in the NRDL in December 2025. Rujianing generated gross sales revenue of approximately RMB25.1 million during the six months ended 30 June 2026. Mulpleta is a TPO receptor agonist for the treatment of thrombocytopenia.

The Agreement provides an integrated framework under which Taizhou EOC will undertake process technology transfer, regulatory filing support, the application for production permits and commercial production and supply, supported by production capacity at Taizhou EOC's facility.

THE AGREEMENT

Date: 17 November 2026

Parties: (i) Eddingpharm Zhuhai (as commissioning party); and

(ii) Taizhou EOC (as commissioned party)

Term: From the date of signing until 31 December 2028, automatically renewable for successive three-year periods, subject to compliance with the continuing connected transaction requirements under the Listing Rules.

Scope:

The scope of the Agreement covers process technology transfer, registration filing support, obtaining the relevant production permits, and commercial production and supply of the Products. The services include:

(i) process development, pilot-scale and validation batch production;

(ii) preparation of pharmaceutical registration filing materials and support for regulatory inspections; and

(iii) commercial production and supply of the Products.

Technology Transfer Service Fee:

The total technology transfer service fee under the Agreement is RMB14,600,000 (inclusive of tax). The fee covers the entire scope of process technology transfer and registration filing support services for the Products.

Pricing Policy:

The pricing of the transactions under the Agreement was determined after arm's length negotiations between the parties:

(a) **Technology Transfer Service Fee:** The technology transfer service fee was determined with reference to comparable market prices for similar technology transfer services, taking into account the technical complexity, delivery timeline and risk allocation.

(b) **Commercial Production Prices:** The commercial production prices for Products were determined with reference to average market transaction prices of products with comparable indications and dosage forms, adopting a cost-plus approach. The cost components include direct material costs, contract processing and labour costs, compliant warehousing and logistics costs.

(c) **Equipment Buyback:** The consideration for the Equipment Buyback was determined with reference to the procurement cost of the equipment to be incurred by Eddingpharm Zhuhai.

The Directors (including the independent non-executive Directors) are of the view that the pricing under the Agreement (including the Equipment Buyback) is fair and reasonable and comparable to those offered by independent third parties.

Equipment Buyback: Eddingpharm Zhuhai will provide the equipment required for production of the Products at a total purchase price of not more than RMB11,000,000, and Taizhou EOC will purchase such equipment from Eddingpharm Zhuhai at a consideration equal to such total purchase price. The equipment is exclusively dedicated to the production of the Products under the Agreement. An amount equal to a lower double-digit percentage of the tax-inclusive total commercial product purchase price payable by Eddingpharm Zhuhai per unit of each Product will be deducted from each sale until the total purchase price of such equipment has been fully offset. Upon full settlement, ownership of the equipment will be transferred to Taizhou EOC. Eddingpharm Zhuhai will retain ownership of the equipment until the total purchase price of such equipment has been fully offset.

Prior to the transfer of ownership of the equipment from Eddingpharm Zhuhai to Taizhou EOC, Taizhou EOC shall be responsible for the proper custody, routine maintenance, repair, upkeep, compliant use and related costs of the equipment, and shall procure insurance coverage (if applicable). Regardless of whether ownership of the equipment has been transferred, Taizhou EOC shall bear the risk of any damage, destruction, loss, theft, seizure or other loss of the equipment caused by Taizhou EOC's improper custody, maintenance or use, or any other reason attributable to Taizhou EOC.

The deduction rate was determined with reference to the production and sales forecast of the Products, so that the expected period for settling the total purchase price of such equipment is in line with the depreciation period of the equipment, while maintaining commercially viable product pricing.

During the term of the Agreement, if the aggregate offset amount has not reached the total purchase price of the equipment, ownership of the equipment shall remain with Eddingpharm Zhuhai. If, upon expiry or early termination of the Agreement, the aggregate offset amount has not reached the total purchase price of such equipment, Taizhou EOC shall have the right to elect, pursuant to the agreement, to pay the shortfall to Eddingpharm Zhuhai to repurchase the equipment; upon Taizhou EOC's election and full payment, ownership of such fixed assets shall transfer to Taizhou EOC. If Taizhou EOC does not elect to repurchase, Eddingpharm Zhuhai shall have the right to recover the equipment and determine their subsequent use or disposal at its discretion.

Commercial Production Pricing:

The commercial production prices for the Products are calculated as the agreed unit price (exclusive of tax) multiplied by the number of units produced. The commercial production prices will remain stable for at least 24 months after the relevant product receives market approval and will be reviewed annually thereafter. Eddingpharm Zhuhai shall have the right to issue formal orders to Taizhou EOC based on rolling procurement forecasts.

Payment Terms:

The technology transfer service fee is payable by milestones: (i) 30% of the total technology transfer service fee to be settled upon signing of the Agreement; and (ii) the remaining 70% to be settled in instalments upon completion of the pre-determined technology transfer milestones set out in the Agreement.

For commercial production, Eddingpharm Zhuhai will settle the Product purchase costs (after deduction of the amount attributable to the Equipment Buyback) within 60 days after all of the following conditions are satisfied: (a) Taizhou EOC has fully and properly performed its obligations under the Agreement and the relevant purchase order; (b) the Products have been delivered and accepted in writing by Eddingpharm Zhuhai; and (c) Eddingpharm Zhuhai has received qualifying invoices from Taizhou EOC.

Intellectual Property Arrangement: Each party retains ownership of its respective intellectual property. All technology transfer results created or generated by Taizhou EOC in the course of providing the commissioned technology transfer and production services under the Agreement (the "**Project Technology Transfer Results**") shall be owned by Eddingpharm Zhuhai, and Taizhou EOC shall assign to Eddingpharm Zhuhai all ownership, copyright, trade secrets, patents and other intellectual property rights in connection with the Project Technology Transfer Results at no additional cost. Where Taizhou EOC independently funds process optimisation, the resulting intellectual property shall be jointly owned by both parties, subject to a separate agreement on the allocation of rights and benefits.

Exclusive Supply: Products produced under the Agreement shall be exclusively supplied to Eddingpharm Zhuhai during the term of the Agreement.

PROPOSED ANNUAL CAPS AND BASIS OF DETERMINATION FOR THE CONTINUING CONNECTED TRANSACTIONS

As the Group has not previously entered into similar transactions with Taizhou EOC for the technology transfer and commercial production of the Products, the proposed annual caps are determined based on reasonable estimates and assumptions rather than historical transaction amounts. The principal assumptions are as follows:

(I) Technology Transfer Service Fees and Commercial Product Purchase Costs

	For the year ended 31 December		
	2026	**2027**	**2028**
	(RMB)	*(RMB)*	*(RMB)*
Aggregate Annual Cap	3,250,000	12,455,000	11,079,419

The above annual caps comprise the technology transfer service fees and commercial product purchase costs aggregated for each corresponding financial year, and are determined on the basis of the amounts actually payable by Eddingpharm Zhuhai, i.e. net of the amounts to be deducted from the Product purchase payments in settlement of the consideration for the Equipment Buyback. The amounts so deducted form part of the consideration for the Equipment Buyback, which constitutes a one-off connected transaction and has been aggregated with the Continuing Connected Transactions for the purpose of classification under Chapter 14A of the Listing Rules. The basis of determination for each component is as follows:

1. Technology Transfer Service Fees:

(i) The technology transfer service fees shall be paid in accordance with milestone payment arrangements;

(ii) As the technology transfer process is subject to factors including equipment and production facility procurement cycles, technical development complexity and the NMPA's review progress and inspection scheduling, the fees corresponding to the same milestone may be recognised in any financial year between the earliest and latest possible trigger dates; and

(iii) In determining the annual cap for each financial year, the Company has adopted a conservative approach by assuming that the relevant milestones may be achieved in any financial year between their earliest and latest possible trigger dates, and has set the annual cap for each year based on the maximum aggregate fees payable under the least favourable milestone combination for that year. As these scenarios are mutually exclusive, the aggregate of the annual caps across the three financial years exceeds the contractual fixed total price for technology transfer services and does not represent the total amount the Group will be required to pay. For the avoidance of doubt, the actual aggregate technology transfer service fees over the three financial years shall not exceed the contractual fixed total price under the Agreement.

2. Commercial Product Purchase Costs:

No commercial product purchase costs for Mulpleta are expected to be incurred in 2026 or 2027. Commercial production of Mulpleta at Taizhou EOC's facility under the Agreement is expected to commence in 2028, with an estimated delivery of three batches. Based on the agreed commercial production price per box (exclusive of tax), the estimated tax-inclusive total purchase costs are RMB3,099,274. The above three batches represent a reasonable estimate by Eddingpharm Zhuhai based on its historical Mulpleta market sales during the term of the Agreement. Part of the commercial product purchase costs will be offset against the Equipment Buyback, and the corresponding amount has been deducted from the 2028 annual cap.

No commercial production costs for Rujianing are expected to be incurred during the term as Rujianing's process validation and registration filing are expected to be completed in the first half of 2028, and commercial production of Rujianing at Taizhou EOC's facility under the Agreement is not expected to commence before expiry of the initial term.

THE EQUIPMENT BUYBACK

The consideration for the Equipment Buyback shall be equal to the total purchase price paid by Eddingpharm Zhuhai for the equipment, which shall not exceed RMB11,000,000. The consideration was determined after arm's length negotiations with reference to the procurement cost of the equipment to be incurred by Eddingpharm Zhuhai.

The consideration shall be settled by way of deduction from the Product purchase payments payable by Eddingpharm Zhuhai at a rate of a lower double-digit percentage of the tax-inclusive total commercial product purchase price per unit, and, where applicable, by payment of the shortfall by Taizhou EOC upon expiry or early termination of the Agreement, as described under "The Agreement – Equipment Buyback" above. The deduction rate is determined with reference to the production and sales forecast, so that the expected period for settling the total purchase price of such equipment is in line with the depreciation period of the equipment, while maintaining commercially viable product pricing.

The equipment is exclusively dedicated to the production of the Products. As the consideration is equal to the purchase price of the equipment, the Group does not expect to recognise any material gain or loss from the Equipment Buyback. The proceeds from the Equipment Buyback will be applied by way of offset against, and will reduce, the Group's purchase costs for the Products.

REASONS FOR AND BENEFITS OF THE AGREEMENT

The Board considers that the entering into of the Agreement is in line with the Group's business needs to advance the localised technology transfer, registration and commercial production of the relevant products and to establish a stable and controllable domestic production and supply system. The technology transfer and commercialisation arrangements under the Agreement are commercially complementary and collectively constitute the Group's overall cooperation framework for deploying dedicated production capacity, advancing technology transfer and securing ongoing supply for the relevant products. The principal reasons for and expected benefits of the transactions under the Agreement are as follows:

1. **Enhancing supply security through dedicated production capacity matched to product demand characteristics.** The Group's existing production base is not currently equipped for co-production of the Products, and therefore is required to engage a qualified third-party contractor to undertake commercial production of the Products. In terms of demand characteristics, Mulpleta, taking into account patient numbers, treatment cycles and batch size requirements, has relatively few annual production batches; while Rujianing is in a rapid growth phase, making market demand forecasting more challenging. These characteristics require the contractor to maintain production line availability and scheduling priority under low-batch scenarios, while also retaining the flexibility for rapid production scale-up and delivery when demand increases. Through equipment deployment, contractor facility modification and commercial production arrangements under the Agreement, dedicated production lines will be established for the Products, with agreed provisions for capacity reservation, procurement forecasting, contingency planning and supply guarantees. These mutually complementary arrangements enable production capacity to be matched to the respective demand characteristics of the two Products, reduce the risk of capacity being displaced by other clients' orders and the additional costs arising from order adjustments, enhance the predictability of supply planning, and provide security for the continuous commercial supply of the Products.

2. **Enhancing quality management and compliance risk control.** The Products are in oral solid dosage forms involving process validation, cleaning validation, co-production line controls and quality release. Taizhou EOC possesses relevant dosage form development, registration and commercial production experience, with complete licenses and qualifications and a well-established quality management system. Dedicated production lines provide greater specificity in production, hygiene and quality control, thereby reducing the quality management complexity associated with cross-contamination and mix-up risks under multi-product co-production.

3. **Improving technology transfer, production and supply chain coordination.** Engaging a single commissioned party to undertake technology transfer, validation, registration support and commercial production within an agreed framework, supported by dedicated equipment and production lines, reduces coordination costs, documentation alignment issues and information transfer risks.

4. **Supporting project implementation through Equipment Buyback.** The arrangement serves to establish dedicated production lines for the Products, which is consistent with prevailing industry practice in pharmaceutical CDMO/contract manufacturing. The Equipment Buyback arrangement links the recovery of the total purchase price of the equipment to actual production and sales volumes, ensuring that the deduction pace aligns with the useful life of the equipment. Prior to full offset of the total purchase price of the equipment, the Group retains ownership of the relevant equipment assets, providing an asset recovery channel and reducing equipment idle and impairment risk. The arrangement helps to bind long-term cooperation between the parties and safeguard continuity and stability of production supply.

5. **Protecting core technology and intellectual property.** Taizhou EOC has an established long-term cooperation foundation with the Group. The dedicated production line arrangement, combined with relatively fixed production, quality and technical personnel, can help narrow the scope and circulation of technical information access. The Agreement also provides for confidentiality obligations, restrictions on use and custody of technical information, personnel management, breach of contract liability and audit rights.

6. **Comprehensive evaluation criteria.** The Group conducted comprehensive assessments of multiple CDMO candidates covering capabilities, compliance, supply assurance, co-production line risks, technology transfer and commercialization quotations. Other CDMO candidates generally rely on shared production lines serving multiple clients, whereas Taizhou EOC proposed a dedicated production line exclusively for the Products, offering structural advantages in production capacity assurance, supply security and cross-contamination risk mitigation.

7. **Verifiable protection of risk allocation and pricing fairness.** The Group will review relevant pricing by reference to cost composition, procurement volumes, comparable market data or third-party information (as applicable) and independent arm's length negotiation results, and will retain audit rights over material cost components and relevant financial records.

The pricing under the Agreement was determined after arm's length negotiations between the parties with reference to comparable quotations from independent third parties.

The Board (including the independent non-executive Directors) considers that the Agreement (including the Equipment Buyback) was entered into in the ordinary and usual course of business of the Group on normal commercial terms or better, and that the terms are fair and reasonable and in the interests of the Company and its Shareholders as a whole.

Shareholders should note that the annual caps represent the best estimates by the Directors based on information currently available. The annual caps bear no direct link, nor constitute a guide or commitment, to the Group's future financial information or performance.

INTERNAL CONTROL MEASURES

In order to safeguard the interests of Shareholders, the Group has formulated the internal control procedures in relation to the Continuing Connected Transactions contemplated under the Agreement to ensure that the above prices of services or products supplied by connected persons are on normal commercial terms and no more favorable than terms available to independent third parties, including but not limited to the following:

(a) The Group will maintain a register of connected persons and a unified compliance file for the Agreement. Prior to signing specific orders, confirming milestones, procuring equipment or products, or changing commercial terms, relevant business, production, quality, procurement, finance and legal personnel will verify the transaction counterparty, pricing, authorisation limits and applicable approval procedures.

(b) Prior to conducting transactions, the business department shall obtain comparable quotations or market reference prices from at least two independent third parties to ensure that terms offered by Taizhou EOC are no less favourable than those available from independent third parties. Individual transactions exceeding prescribed thresholds shall require further approval by management and the Board (as applicable).

(c) The finance department will review all prices and fees under the Agreement in accordance with the agreed pricing mechanism and maintain an overall monitoring ledger and early warning mechanism, regularly reporting to management on actual transaction amounts, outstanding balances and annual cap utilisation. Transactions expected to exceed agreed annual caps will be reassessed and applicable compliance requirements completed before execution.

(d) The production operations department will exercise ongoing supervision over dedicated equipment and production lines, including verifying equipment procurement, installation, acceptance, asset registration, custody, maintenance and compliant use, and will conduct periodic on-site or remote inspections.

(e) The independent non-executive Directors and the auditors of the Company will conduct annual reviews of the applicable Continuing Connected Transactions under the Agreement in accordance with the Listing Rules.

INFORMATION ON THE PARTIES

Information of the Group

The Group is a biopharmaceutical company with two differentiated frontier technology platforms for large-molecule biologics and innovative small nucleic acid therapeutics, covering the entire lifecycle from early-stage drug target discovery, molecular structure design and optimization, IND-enabling studies, clinical development and regulatory submission through to commercialization. Its major therapeutic areas include oncology, autoimmune diseases, chronic inflammation, cardiometabolic diseases and respiratory diseases. The Group's commercialized product portfolio comprises originator-branded products and innovative products, including Rujianing, a novel CDK4/6 inhibitor launched in China and included in the NRDL in December 2025, and Mulpleta, a TPO receptor agonist.

Information of Eddingpharm Zhuhai

Eddingpharm Zhuhai is an indirect wholly-owned subsidiary of the Company incorporated in the PRC. It is responsible for the Group's pharmaceutical development and commercialization activities in the PRC.

Information of Taizhou EOC

Taizhou EOC is an integrated biotech company incorporated in the PRC in October 2021. Taizhou EOC is owned as to approximately (i) 61.20% by EOC Pharma Limited (which was in turn controlled as to approximately 62.34% by Mr. Ni), (ii) 1.73% by Eddingpharm International (which was in turn controlled as to approximately 90.52% by Mr. Ni). Taizhou EOC mainly focuses on the discovery, research and development of innovative oncology products.

LISTING RULES IMPLICATIONS

Taizhou EOC is owned as to approximately (i) 61.20% by EOC Pharma Limited (which was in turn controlled as to approximately 62.34% by Mr. Ni), (ii) 1.73% by Eddingpharm International (which was in turn controlled as to approximately 90.52% by Mr. Ni). Accordingly, Taizhou EOC is an associate of the Controlling Shareholders and a Director and is therefore a connected person of the Company under the Listing Rules.

Accordingly, the transactions contemplated under the Agreement (other than the Equipment Buyback) constitute continuing connected transactions, and the Equipment Buyback constitutes a one-off connected transaction, of the Company under Chapter 14A of the Listing Rules.

Pursuant to Rule 14A.81 of the Listing Rules, the Continuing Connected Transactions and the Equipment Buyback are aggregated as they were entered into with the same connected person under the same agreement. As the applicable percentage ratios (as defined under Rule 14.07 of the Listing Rules) in respect of the proposed annual caps for the Continuing Connected Transactions and the maximum consideration for the Equipment Buyback, on an aggregated basis, exceed 0.1% but all are less than 5%, the transactions under the Agreement are subject to the reporting, announcement and, in the case of the Continuing Connected Transactions, annual review requirements, but exempt from the circular and independent shareholders' approval requirements, under Chapter 14A of the Listing Rules.

At the meeting of the Board, Mr. Ni, the Chairman and an executive Director, has abstained from voting on the Board resolution to approve the Agreement, the Equipment Buyback and the annual caps thereunder due to the fact that Mr. Ni has equity interests in Taizhou EOC. Save as disclosed above, none of the other Directors have any material interest in the Agreement, or were required to abstain from voting on the resolutions of the transactions thereunder.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

"Agreement"	the Technology Transfer and Commercial Production Agreement entered into between Eddingpharm Zhuhai and Taizhou EOC on 17 November 2026
"Board"	the board of Directors of the Company
"CDMO"	contract development and manufacturing organisation
"Company"	Edding Genor Group Holdings Limited (亿腾嘉和醫藥集團有限公司), an exempted company with limited liability incorporated under the laws of the Cayman Islands, the Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 6998)
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"connected transaction(s)"	has the meaning ascribed to it under the Listing Rules

"Continuing Connected Transactions"	has the meaning ascribed to it under the section headed "Implications under the Listing Rules" in this announcement
"Controlling Shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"Director(s)"	the director(s) of the Company
"Eddingpharm International"	Eddingpharm International Holdings Limited (亿腾醫藥國際控股有限公司), a company incorporated in the Cayman Islands with limited liability on 17 April 2012
"Eddingpharm Zhuhai"	Eddingpharm (Zhuhai) Co., Ltd. (亿腾醫藥(珠海)有限公司), an indirect wholly-owned subsidiary of the Company incorporated in the PRC
"Equipment Buyback"	the buyback of equipment by Taizhou EOC from Eddingpharm Zhuhai at a consideration of not more than RMB11,000,000 through deductions from commercial product purchase payments at a rate of a lower double-digit percentage of the tax-inclusive total commercial product purchase price per unit, and, where applicable, payment of the shortfall as contemplated under the Agreement
"Group"	the Company and its subsidiaries from time to time
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Mr. Ni"	Mr. Ni Xin (倪昕), the Chairman, an executive Director and the president of the Group
"NMPA"	China National Medical Products Administration
"NRDL"	National Reimbursement Drug List

"PRC" or "China"	the People's Republic of China, which for the purpose of this announcement excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Products"	Rujianing and Mulpleta
"RMB"	Renminbi, the lawful currency of the PRC
"Rujianing"	Lerociclib Hydrochloride Tablets (鹽酸來羅西利片), 50mg, product name: Rujianing (汝佳寧)
"Share(s)"	ordinary share(s) in the share capital of the Company
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Taizhou EOC"	Taizhou Edding Genor Pharmaceutical Co., Ltd. (泰州亿腾景昂藥業股份有限公司), a company incorporated in the PRC
"Mulpleta"	Lusutrombopag Tablets (蘆曲泊帕片), 3mg, product name: Mulpleta (穩可達)
"%"	per cent

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 17 November 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.